2008 Executive Summary

highlights
Opening of the first The Body Shop stores in Egypt
and Slovakia, and strategic acquisition of
franchisees in Spain.
Development of three new Community Trade
supplier relationships in Kenya, Samoa and
Ecuador.
Launch of Nature’s Minerals , a make-up range
with 100% minerals, fragrance and preservative
free, offering the highest sun protection factor in
its category.
Introduction of 100% recycled PET bottles.
Since 2003, The Body Shop has raised nearly £1.2
million to help women who are victims of domestic
violence, as part of the Stop Violence in the Home
campaign. In addition, the RSPCA (Royal Society for
the Prevention of Cruelty to Animals) awarded it
a prize for its longstanding commitment to
animal welfare. In 2009, the brand will publish its
Values Report, following a review by independent
experts.
—THE BODY SHOP
100% recycled
PET bottles.
GALDERMA
Science in the service of dermatologists
Dedicated exclusively to dermatology and with innovation and research at the
heart of its strategy, Galderma’s ambition is to be recognised as the most
competent and innovative company in its field.
Galderma experienced an exceptional year and
continued to gain market share in its traditional
markets, particularly in North America where
sales increased by 18.5%. The main growth
drivers were Differin ® and Epiduo (acne),
Rozex ® /Metro ® and Oracea ® (rosacea), Clobex ®
(psoriasis), Dysport ® (frown lines) and Cetaphil ®
(therapeutic skincare line).
Through the acquisition of CollaGenex in the
United States, Galderma has enhanced its
product portfolio with Oracea ® , the first oral
treatment for rosacea authorised by the FDA
(Food and Drug Administration), as well as
two topical products which are under
development.
In Japan, the second largest dermatology
market in the world, the launch of Differin ®
represented an important landmark. This
product for acne is the first topical retinoid
approved in the country.
Epiduo has successfully gained ground in Latin
America and Europe.
Galderma has entered the corrective and
aesthetic dermatology market with the launch
of Dysport ® in Latin America. The European
launch, under the Azzalure ® brand name, is
scheduled for 2009.
Some fifty patents have been filed to protect
innovation and numerous products have been
registered.
+17.1%
sales growth like-for-like in 2008
In 2009, Galderma will continue its worldwide rollout
of Epiduo , in the United States in particular,
where it was approved at the end of 2008. Vectical ® ,
for the treatment of psoriasis, will enhance the
American subsidiary’s product range. Several
strategic products will be launched in Europe:
Oracea ® , Clobex ® Shampoo and Azzalure ® .
—GALDERMA
Differin ® .
€854 million
in sales generated in 2008
—GALDERMA
Epiduo GALDERMA
.
17